- Home
- EURK vs IXHL Comparison
EURK vs IXHL Comparison
Compare EURK & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EURK
- IXHL
- Stock Information
- Founded
- EURK 2023
- IXHL 2001
- Country
- EURK Hong Kong
- IXHL Australia
- Employees
- EURK N/A
- IXHL N/A
- Industry
- EURK
- IXHL
- Sector
- EURK
- IXHL
- Exchange
- EURK NYSE
- IXHL Nasdaq
- Market Cap
- EURK 80.7M
- IXHL 78.7M
- IPO Year
- EURK 2024
- IXHL N/A
- Fundamental
- Price
- EURK $10.59
- IXHL $1.05
- Analyst Decision
- EURK
- IXHL
- Analyst Count
- EURK 0
- IXHL 0
- Target Price
- EURK N/A
- IXHL N/A
- AVG Volume (30 Days)
- EURK 24.2K
- IXHL 163.1M
- Earning Date
- EURK 01-01-0001
- IXHL 05-15-2025
- Dividend Yield
- EURK N/A
- IXHL N/A
- EPS Growth
- EURK N/A
- IXHL N/A
- EPS
- EURK N/A
- IXHL N/A
- Revenue
- EURK N/A
- IXHL $98,000.00
- Revenue This Year
- EURK N/A
- IXHL $2,538.49
- Revenue Next Year
- EURK N/A
- IXHL $249.95
- P/E Ratio
- EURK N/A
- IXHL N/A
- Revenue Growth
- EURK N/A
- IXHL N/A
- 52 Week Low
- EURK $10.03
- IXHL $0.08
- 52 Week High
- EURK $10.83
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- EURK N/A
- IXHL 65.21
- Support Level
- EURK N/A
- IXHL $0.21
- Resistance Level
- EURK N/A
- IXHL $1.66
- Average True Range (ATR)
- EURK 0.00
- IXHL 0.15
- MACD
- EURK 0.00
- IXHL 0.11
- Stochastic Oscillator
- EURK 0.00
- IXHL 57.99
About EURK EUREKA ACQUISITION CORP
Eureka Acquisition Corp is a newly incorporated blank check company.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.